We continually work to improve the affordability of medicines around the world by investing manufacturing capital in cGMP compliant and globally licensed facilities.
We have leveraged and invested in our manufacturing capital through cGMP compliant and globally certified facilities. This has enabling the company to become a global leader in the pharmaceutical sector.
Our consistent and timely delivery of reliable products has increased patient and healthcare professional confidence in our products. We remain committed to maintaining that trust by manufacturing high-quality pharmaceuticals with integrity and introducing innovative and breakthrough technologies to provide the highest quality products.
We continue our “Care for Life” principle and work to improve the affordability of medicines around the world. This has been achieved by streamlining costs and complexity, improving product portfolios, improving processes/yields and developing alternative suppliers.
Our capabilities include proprietary and licensed facilities that support biotech businesses. Investing in manufacturing capital includes developing new drug delivery systems, facilitating infrastructure to support API and formulation development, and enhancing platform technology.
In addition to new facilities, all existing facilities are regularly upgraded to meet current cGMP, safety, health, and environmental standards.
M S Khan
Chariman
